PI3K Inhibitor Resistance Reversed in Lab Study
Researchers discover a molecular mechanism involving the AR-UBE2C axis to improve treatment efficacy in certain cancers.
Updated on Oct. 16, 2026 in Cancer
Scientists have identified a mechanism that allows breast and prostate cancer cells to resist PI3K inhibitors. Combining these drugs with anti-androgen therapy successfully restores the ability to kill resistant cancer cells in preclinical models.
Why it matters
High expression of the AR-UBE2C axis prevents drug-induced autophagy and cell cycle arrest in resistant tumors. Targeting this axis could lead to more effective treatment strategies for patients who do not respond to standard PI3K inhibition.
Compound 8, a novel fluorinated isoflavone derivative, acts as a PI3K inhibitor in this study. Researchers found that high levels of UBE2C protein suppress autophagy-associated cell death, directly contributing to drug resistance.
The players
Enzalutamide
Enzalutamide is an anti-androgen medication used to block androgen receptor signaling in cancer cells.
Compound 8
Compound 8 is a fluorinated isoflavone derivative acting as a PI3K inhibitor.
The details
The study reveals that high androgen receptor abundance upregulates UBE2C expression to maintain autophagy inhibition. By using Enzalutamide to pharmacologically inhibit the androgen receptor, the research team successfully restored cytotoxic activity in previously resistant cancer cells.
Timeline
October 16, 2026: The research findings were published.
The Big Picture
This discovery shifts the understanding of PI3K/AKT/mTOR signaling pathway research by identifying a specific resistance mechanism. It builds on established molecular models to suggest that combined therapies can bridge the gap between initial treatment and resistance.
This laboratory-stage breakthrough may eventually lead to new combined treatment options for patients with resistant breast or prostate cancer. Clinical trials will be necessary to confirm if these results translate into safe and effective care for humans.
The takeaway
Resistance to cancer therapies often involves complex protein interactions like the AR-UBE2C axis. Addressing these pathways in tandem with primary drugs offers a promising strategy to improve patient outcomes in the future.
Further reading
Learn more about new therapeutic developments in Cancer
Source note: This article includes information reported by Nature.
